The FDA on April 30, 2018 granted regular approval to TAFINLARĀ® (Dabrafenib) and MEKINISTĀ® (Trametinib), in combination, for the adjuvant treatment of patients with Melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. TAFINLARĀ® and MEKINISTĀ® are products of Novartis Pharmaceuticals Corp.
Other Pages – Bottom Ad
Advertisement
Subscribe
